Selank and Semax: Russian Nootropic Peptide Research
PeptaBase Research Review | 2026-01-31
Origins and Development Context
Selank and Semax were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Both are approved pharmaceuticals in Russia with decades of clinical use there. Outside Russia, they're research compounds. Most published studies are in Russian journals, which makes the evidence harder to access and verify independently.
Selank: Structure and Mechanism
Selank (TP-7) is a 7-amino-acid peptide engineered from tuftsin, a natural immune-related peptide. Researchers added three amino acids to the original sequence to make it last longer in the body.
Selank's main studied effect is reducing anxiety. Research suggests it works by modulating GABA receptors, affecting serotonin, and boosting BDNF and IL-6 in the brain. Animal studies show decreased anxiety in standard tests. Russian clinical trials have examined it for generalized anxiety disorder.
The extra amino acids make Selank more stable than natural tuftsin, so it stays in the body longer before being broken down.
Semax: Structure and Mechanism
Semax is a 7-amino-acid peptide based on a fragment of ACTH. Like Selank, it has the stability-boosting Pro-Gly-Pro tail attached. Unlike ACTH itself, Semax doesn't affect cortisol production-it lacks the necessary structure to activate ACTH receptors.
Research focuses on Semax's neuroprotection and cognitive effects. Animal studies show it increases BDNF and nerve growth factor (NGF) in the brain. In ischemic stroke models, Semax reduces brain damage and improves recovery. Russian clinicians use it for stroke and cognitive decline.
Intranasal Administration
Both Selank and Semax are delivered through the nose. This route sidesteps the liver's first-pass metabolism and may allow the peptides to reach the brain directly along the olfactory and trigeminal nerves-partially bypassing the blood-brain barrier. That matters because peptides are hard to get into the brain through the bloodstream alone.
Research Status: Russia vs. Western Literature
In Russia, both peptides are approved drugs used in clinical practice. There's substantial published evidence from Russian trials, but most studies are small and lack the placebo controls required by Western regulatory agencies. Western researchers haven't independently replicated the findings, and neither peptide has gone through Western approval pathways.
The mechanisms-BDNF boost, GABA effects, neuroprotection-make scientific sense and fit with what neuroscientists know about brain repair. But by Western clinical trial standards, the evidence is still preliminary.
--- For research use only. Not medical advice.